CEO Blog: June is off to an amazing start

Dear shareholders and friends,

June is off to an amazing start for US Stem Cell Inc!  Our team is continuing to grow as we open new clinics—and we will be announcing several new locations in the coming months.  The message about regenerative medicine is beginning to reach a larger and broader audience.  In fact, the State of Texas has already approved legislation providing access to stem cell therapies to patients in need—and many other states are positioned to follow (see  We at U.S. Stem Cell commend the State of Texas for their forward-thinking support of patients in need, as we in turn prepare to open our next clinic in Dallas.

Earlier this month, our Chief Scientific Officer, Kristin Comella, was featured on Dr. Joseph Mercola’s blog with over 1.5 million followers demonstrating additional proof that stem cell options are reaching more folks.  Click here to read/listen:  In addition, Comella has been recognized as one of Miami Today’s Best of Miami Health & Medicine for her work in regenerative medicine and stem cell therapy.  Access the full article here:  On June 5th, Comella also spoke to the Women’s Club at the Michael-Ann Russell JCC about harnessing your body’s healing potential by using adipose (fat) stem cells. She discussed joint issues, inflammation and issues after childbirth.  View here for more:

And the accolades for our research also continues.  Our scientific paper about intramyocardial implantation co-authored by Comella has recently been recognized as one of the most influential articles of 2016 for the Journal of Translational Medicine according to  Read more here:

As many of you know, we have been working with the FDA regarding Regenerative Medicine Advanced Therapy (RMAT) designation for our MyoCell™ product. The RMAT process with the FDA has been quite cumbersome, time consuming and interactive as each request for additional information restarts the FDA’s 60-day clock—and the clock again restarting when we provided additional input on the $100,000,000 in clinical research we have invested on Myocell research thus far.  As a small company with limited resources, this process has proven unsustainable until the FDA determines an equitable path for all companies applying—which is apparently not the case today.  Even if approved for RMAT, we are still uncertain as to what the designation would mean for our company nor how we could benefit our patients in need.  U.S. Stem Cell cannot afford to continue this undetermined path so at this time, we have decided not to further invest funds in pursuing RMAT Designation and instead focus on our in-clinic therapies for patients.  According to the 21st Century Cures Act, the FDA has one year to issue draft guidance clarifying how the FDA will evaluate devices used in the recovery, isolation, or delivery of regenerative advanced therapies. Until this guidance document is published, it is unclear how this regulation will affect the MyoCell program.  Due to the uncertainty of this program, we feel that our shareholders and patients will be better served if we focus our efforts on therapies that benefit patients RIGHT NOW.  For this reason, we will instead focus on our revenue generating programs which have successfully helped over 7,000 patients. We at US Stem Cell Inc are very bullish on newly appointed FDA commissioner Scott Gottlieb as he promises to be a transformational leader for both the FDA and the progress of stem cell solutions for patients in need.  See his article on the subject here

Our company was founded in 1999 and has completed more clinical treatments (for both humans and animals) than any other regenerative medicine company in the world.  We are currently expanding and opening additional clinics throughout the U.S. to offer these cutting-edge technologies to more patients.  We are thrilled to see the excitement about our technologies and will continue to pave the future of medicine.  Our shareholders demand that we focus our resources on helping patients in need TODAY—and we agree.

Warmest regards,

Mike Tomas
President &CEO
US Stem Cell Inc.